<DOC>
	<DOCNO>NCT00004127</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine oxaliplatin fluorouracil leucovorin treat patient recurrent metastatic cancer esophagus stomach .</brief_summary>
	<brief_title>Oxaliplatin Combined With Fluorouracil Leucovorin Treating Patients With Recurrent Metastatic Cancer Esophagus Stomach</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient recurrent metastatic carcinoma esophagus gastric cardia receive combination oxaliplatin , fluorouracil , leucovorin calcium . II . Determine duration response overall survival patient population receive regimen . III . Determine toxicity , include neurotoxicity , regimen patient population . OUTLINE : This open-label , multicenter study . Patients receive oxaliplatin IV 2 hour day 1 , leucovorin calcium IV 2 hour fluorouracil IV bolus , follow fluorouracil IV 22 hour day 1 2 . Treatment continue every 2 week minimum 3 course absence disease progression unacceptable toxicity . Patients stable respond disease receive least 3 additional course therapy . Patients follow minimum 2 year death . PROJECTED ACCRUAL : A total 12-37 patient accrue study 18 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma esophagus gastric cardia Stage IV recurrent Bidimensionally measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 10 g/dL Hepatic : Bilirubin normal SGOT le 2 time upper limit normal ( ULN ) Renal : BUN le 1.5 time ULN Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No congestive heart failure No unstable angina pectoris No myocardial infarction within past 6 month Other : Not pregnant nursing Fertile patient must use effective contraception 6 month study No allergy platinum compound antiemetic appropriate study No uncontrolled concurrent illness No active infection No clinical evidence peripheral neuropathy physical exam history PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colonystimulating factor first course study Chemotherapy : More 4 week since prior chemotherapy No 1 prior chemotherapy regimen carcinoma esophagus gastric cardia No prior fluorouracil Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : No concurrent investigational agent No concurrent antiretroviral therapy HIVpositive patient No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>